Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.090 -0.030 (-2.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
34 35 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Viridian Therapeutics (NASDAQ:VRDN) stock rose 22.49% to $19.17 during Tuesday's pre-market session. The company's market cap stands at $331.8 million. Inhibrx (... 
Via Benzinga
15 Stocks Moving in Tuesday's Pre-Market Session
Gainers Quanterix Corporation (NASDAQ: QTRX) shares rose 17.6% to $48.55 in pre-market trading after the company announced its Simoa phospho-Tau 181 blood test has been granted... 
Via Benzinga
Don’t Buy Too Much Into the WHO Hype Surrounding Ocugen Stock
The latest buzz around Covaxin does little to improve the prospects of OCGN stock, so buying it for this reason doesn't make much sense. 
Via InvestorPlace
Why Did Ocugen Stock Skyrocket On Monday?
Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 8.8% in Monday’s regular trading session and also gained 11.4% in the after-hours session. What... 
Via Benzinga
OCUGEN INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN
From Kahn Swick & Foti, LLC
Via Business Wire
WHO To Finalize Nod To Ocugen-Partnered Covaxin Next Week: Sources
The World Health Organization said a decision on the Emergency Use Listing (EUL) of India's COVID-19 vaccine, Covaxin, will be finalized next week. Ocugen Inc (... 
Via Benzinga
Ocugen Bulls Are Overlooking Its FDA Approval Hurdles
The FDA seems highly unlikely to approve the Covaxin vaccine, making OCGN stock an excellent name to short going forward. 
Via InvestorPlace
OCGN Stock: 2 Huge Reasons Ocugen Stock Is Shooting Higher Today
OCGN stock is surging on some big news. The World Health Organization could give the company the go-ahead on its Covid-19 vaccine very soon. 
Via InvestorPlace
Why Ocugen Shares Are Trading Higher Today
Ocugen Inc (NASDAQ: OCGN) is trading higher Tuesday after a company 8-K showed it entered into a Development and Commercial Supply Agreement with Bharat Biotech pursuant to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ocugen (NASDAQ:OCGN) shares moved upwards by 11.11% to $7.5 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.4... 
Via Benzinga
WHO Approval Won’t Move Ocugen Stock Very Much Over the Long Term
The WHO's nod of approval wont be fruitful to OCGN stock in blowing past the regulatory hurdles in the North American Covid 19 vaccine market. 
Via InvestorPlace
16 Stocks Moving in Tuesday's Pre-Market Session
Gainers Marine Petroleum Trust (NASDAQ: MARPS) rose 25.4% to $6.29 in pre-market trading after gaining 8% on Monday. Agrify Corporation. (NASDAQ: AGFY) rose 17.8% to $21.76 in... 
Via Benzinga
WHO To Decide On EUL Of Ocugen-Partnered COVID-19 Vaccine Today
An expert panel of the World Health Organization (WHO) will decide on the emergency use listing (EUL) authorization of Covaxin today. Covaxin is India's indigenously-... 
Via Benzinga
Ocugen Stock Just Needs a Catalyst to Break Free
OCGN stock holders should be patient as the World Health Organization's potential approval of an important vaccine could happen soon. 
Via InvestorPlace
It’s Time To Drop Ocugen Stock While You Still Can
Hope is one thing, but for OCGN stock investors expecting regulators or other bulls to come to the rescue, things are starting to look gloomy. 
Via InvestorPlace
Ocugen Still Lacks a Path to U.S. Profits
Ocugen still lacks a proper catalyst and nothing has changed for it. As a result, investors should avoid OCGN stock. 
Via InvestorPlace
Ocugen, Inc. (NASDAQ:OCGN) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 09/28/2021 -- Certain directors of Ocugen, Inc are under investigation concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc. 
Via SBWire
Topics Lawsuit
Ocugen-Partnered Covaxin's WHO Clearance Delayed Further Over Queries: Sources
The World Health Organization (WHO) has further delayed the emergency use authorization (EUA) for Covaxin, a COVID-19 vaccine developed in India. Ocugen Inc (NASDAQ:... 
Via Benzinga
Is Ocugen Worth Another Look After Good News for COVID Vaccine Covaxin?
An anticipated emergency use listing for the vaccine won't help Ocugen. 
Via The Motley Fool
Ocugen's India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report
India-based Bharat Biotech has completed the Phase 2 and 3 trials of COVID-19 vaccine, Covaxin, for use in 2 to 18 years. Ocugen Inc (NASDAQ: OCGN... 
Via Benzinga
It’s OK to Sell the News on Ocugen and Covaxin
OCGN stock jumped when Covaxin received WHO approval. But with two major obstacles in the way of U,S. approval, you should sell the news. 
Via InvestorPlace
Could This News Spark a Turnaround for Ocugen?
Ocugen shares soared more than 700% early in the year. They've since lost half of the gain. 
Via The Motley Fool
Why COVID Vaccine Stocks BioNTech, Moderna, and Novavax Are Sliding While Ocugen Is Rising
Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision. 
Via The Motley Fool
I’d Take Nio Stock’s 12-Month Double Despite Falling Below $50
A $10,000 investment in NIO stock a year ago is worth more than $20,000 today. From here, under $40 remains a great entry point if you want to make money over the long haul. 
Via InvestorPlace
Topics Electric Vehicles
WHO Approval Should Get Ocugen Stock Over the $15 Barrier
Sharp up-and-down moves in OCGN stock shouldn't scare investors away, as a regulator's nod for Covaxin should put the stock back on track. 
Via InvestorPlace
Here’s What the Charts Say About Ocugen Stock Now
Ocugen is a high-risk, high-reward speculative play. The charts for OCGN stock show some promise, but here's the level it has to hold above. 
Via InvestorPlace
OCGN Stock: Why Ocugen Shares Are Shooting Higher Today
The WHO could be about to green light a vaccine from one of Ocugen's partners, but that doesn't mean OCGN stock will stay in the green. 
Via InvestorPlace
72 Biggest Movers From Yesterday
Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead... 
Via Benzinga
Where's Ocugen Stock Headed Monday And Why?
Ocugen Inc. (NASDAQ: OCGN) shares were trading higher Monday, after Bharat Biotech: a company partner, was given the nod for a COVID-19 vaccine by the World Health Organization.... 
Via Benzinga
Here's Why Ocugen Is Skyrocketing Today
There's both good and bad news for this troubled coronavirus vaccine biotech. 
Via The Motley Fool
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.